Development of siRNA-loaded chitosan nanoparticles targeting Galectin-1 for the treatment of glioblastoma multiforme via intranasal administration

Item Type:	Article
Title:	Development of siRNA-loaded chitosan nanoparticles targeting Galectin-1 for the treatment of glioblastoma multiforme via intranasal administration
Creators Name:	Van Woensel, M. and Wauthoz, N. and Rosière, R. and Mathieu, V. and Kiss, R. and Lefranc, F. and Steelant, B. and Dilissen, E. and Van Gool, S.W. and Mathivet, T. and Gerhardt, H. and Amighi, K. and De Vleeschouwer, S.
Abstract:	Galectin-1 (Gal-1) is a naturally occurring galactose-binding lectin, which is overexpressed in glioblastoma multiforme (GBM). Gal-1 is associated with tumor progression, and is a potent immune suppressor in the tumor micro-environment. To inhibit Gal-1 in GBM, an effective therapy is required that reaches the central nervous system tumor, with limited systemic effects. In this study, we report for the first time that concentrated chitosan nanoparticle suspensions can deliver small interfering RNA (siRNA) into the central nervous system tumor within hours after intranasal administration. These nanoparticles are able to complex siRNA targeting Gal-1 to a high percentage, and protect them from RNAse degradation. Moreover, a successful intracellular delivery of anti-Gal-1 siRNA resulted in a decreased expression of Gal-1 in both murine and human GBM cells. Sequence specific RNAinterference, resulted in more than 50% Gal-1 reduction in tumor bearing mice. This study indicates that the intranasal pathway is an underexplored transport route for delivering siRNA-based therapies targeting Gal-1 in the treatment of GBM.
Keywords:	Chitosan, Nanoparticles, siRNA, Galectin-1, Glioblastoma, Intranasal, Animals, Mice
Source:	Journal of Controlled Release
ISSN:	0168-3659
Volume:	227
Page Range:	71-81
Date:	10 April 2016
Official Publication:	https://doi.org/10.1016/j.jconrel.2016.02.032
PubMed:	View item in PubMed

Repository Staff Only: item control page